Pharmascience

Type: Company
Name: Pharmascience
First reported Sep 19 2014 - Updated Sep 19 2014 - 1 reports

Notice of Results

Oxford Pharmascience Group plc("Oxford Pharmascience" or the "Company") Oxford Pharmascience, the specialty pharmaceutical company that redevelops medicines to make them better, safer and easier to take, will announce its unaudited interim results for ... [Published MoneyAM - Sep 19 2014]
First reported Sep 17 2014 - Updated Sep 17 2014 - 4 reports

OLEX™ (20mg Omeprazole Delayed-release Tablets) - A New Option For Canadians Suffering From Frequent Heartburn

MONTRÉAL, Sept. 17, 2014An effective non-prescription treatmentOLEX (omeprazole delayed-release tablets) is an important new addition to heartburn solutions already available without a prescription. Unlike antacids, that temporarily neutralise stomach ... [Published TheStreet.com - Sep 17 2014]
First reported Sep 15 2014 - Updated Sep 15 2014 - 5 reports

UPDATE - Oxford Pharmascience making strides

---ADDS BROKER COMMENT AND SHARE PRICE--- Oxford Pharmascience ( LON:OXP ) is ready to scale-up manufacturing of its reduced gastric irritation (GI) formulation of naproxen. The company has successfully synthesised taste masked naproxen, a non-steroidal ... [Published Proactiveinvestors United Kingdom RSS feed - Sep 15 2014]
First reported Sep 15 2014 - Updated Sep 15 2014 - 1 reports

Stock Analysts’ Ratings Reiterations for September, 15th (AHCG, ALL, ANN, APC, ASC, AVN, AVV, BDEV, BKG, BOO)

Stock Analysts’ ratings reiterations for Monday, September 15th: Apc Technology Group PLC (LON:APC) Apc Technology Group PLC (LON:APC) Avanti Communications Group PLC (LON:AVN) Berkeley Group Holdings PLC (LON:BKG) Brewin Dolphin Holdings plc (LON:BRW) ... [Published American Banking News - Forex - Sep 15 2014]
First reported Jul 18 2014 - Updated Jul 18 2014 - 1 reports

Syrian Arab Republic: Syrian man can smile again thanks to treatment

Source: Health Partners International of CanadaCountry: Syrian Arab Republic A Syrian man in his early 20s was injured during the civil war in his country when a bomb hit his neighbourhood. Shrapnel had struck his neck and made him a quadriplegic. “I ... [Published ReliefWeb - Latest Updates - Jul 18 2014]
First reported Jul 15 2014 - Updated Jul 16 2014 - 2 reports

Pendopharm gets Health Canada approval for hepatitis C drug Ibavyr

Pendopharm, a division of Pharmascience, has secured Health Canada approval and market availability of IBAVYR (ribavirin tablets), the first stand-alone oral ribavirin for the treatment of chronic hepatitis C virus (HCV) infections in Canada.The drug ... [Published Pharmaceutical Business Review - Jul 16 2014]
First reported Jul 16 2014 - Updated Jul 16 2014 - 1 reports

Oxford Pharmascience appoints new non-exec

Oxford Pharmascience ( LON:OXP ) announced it has appointed veteran investor Karl Robertson Van Horn to its board as a non-executive director. Van Horne, age 79, has had a distinguished multinational career in senior positions across investment management, ... [Published Proactiveinvestors United Kingdom RSS feed - Jul 16 2014]
First reported Jun 17 2014 - Updated Jun 17 2014 - 2 reports

UPDATE - Oxford Pharmascience scores line extension in Brazil

---ADDS BROKER COMMENT AND SHARE PRICE--- Oxford Pharmascience ( LON:OXP ) has agreed a line extension in Brazil with its partner Aché Pharmaceuticos. The UK company specialises in redeveloping medicines to make them better, safer and easier to take, ... [Published Proactiveinvestors United Kingdom website - Jun 17 2014]
First reported Jun 02 2014 - Updated Jun 02 2014 - 3 reports

UPDATE - Oxford Pharmascience pleased with "fantastic" NSAID trial result

---ADDS BROKER & CEO COMMENTS PLUS SHARE PRICE REACTION--- Oxford Pharmascience ( LON:OXP ) said the primary and second end points were met in its pilot clinical study of OXP001, its non-steroidal anti-inflammatory drug (NSAID). Oxford, which specialises ... [Published Proactiveinvestors United Kingdom RSS feed - Jun 02 2014]
First reported May 28 2014 - Updated May 28 2014 - 1 reports

Major Discovery on the Mechanism of Drug Resistance in Leukemia and Other Cancers

A mechanism that enables the development of resistance to Acute Myeloid Leukemia (AML) anticancer drugs, thereby leading to relapse, has been identified by Kathy Borden of the University of Montreal's Institute for Research in Immunology and Cancer (IRIC) ... [Published Science Daily - May 28 2014]
First reported Apr 30 2014 - Updated Apr 30 2014 - 1 reports

Oxford Pharmascience appoints clinical partner for Safestat study

Oxford Pharmascience Group ( LON:OXP ) has appointed contract research organisation Quotient Clinical to conduct the proof of concept study for its Safestat atorvastatin product. Oxford, which redevelops medicines to make them better, safer and easier ... [Published Proactiveinvestors United Kingdom RSS feed - Apr 30 2014]
First reported Apr 04 2014 - Updated Apr 04 2014 - 1 reports

ValiRx, e-Therapeutics, Oxford Pharmascience and Action Hotels to present next week

Next week's Proactive forum promises to be a dynamic evening as it showcases some of the most exciting non-resource companies, which are hot on the market right now. Joining us on Thursday, April 10 at the Chesterfield Mayfair Hotel will be ValiRx ... [Published Proactiveinvestors United Kingdom RSS feed - Apr 04 2014]

Quotes

"We are now prioritising our work to demonstrate that reduced gastric irritation is a class effect for NSAIDS formulated using our technology and also to establish comparable absorption vs. standard (generic) ibuprofen and naproxen. Our aim is build a robust clinical data package to enable the commercialisation of a number of NSAID assets in 2015 and beyond" Bravo revealed
"We believe that moving forward with the four main NSAIDs in parallel represents a more compelling proposition for adding further shareholder value, as it increases the potential licensing scope and value of applying our technology across multiple products in the anti-inflammatory pain relief category" said Chief Executive Marcelo Bravo in a statement
"Oxford Pharmascience has made great progress applying its technology to other NSAIDs and we are excited by the progression of naproxen into scale-up and readiness for Oxford Pharmascience Group Plc"
"Now, PENDOPHARM will work closely with the provinces to ensure patients have access to IBAVYR and all-oral treatments as quickly as possible, in order to achieve high cure rates while improving quality of life." Latest News

More Content

All (40) | News (31) | Reports (0) | Blogs (7) | Audio/Video (0) | Fact Sheets (0) | Press Releases (2)
sort by: Date | Relevance
Notice of Results [Published MoneyAM - Sep 19 2014]
OLEX™ (20mg Omeprazole Delayed-release Tablets)... [Published TheStreet.com - Sep 17 2014]
OLEX(tm) (20mg omeprazole delayed-release table... [Published Finwin - Sep 17 2014]
OLEX™ (20mg omeprazole delayed-release tablets)... [Published Ask.com - Sep 17 2014]
OLEX™ (20mg omeprazole delayed-release tablets)... [Published Stock Nod - Sep 17 2014]
UPDATE - Oxford Pharmascience making strides [Published Proactiveinvestors United Kingdom RSS feed - Sep 15 2014]
Stock Analysts’ Ratings Reiterations for Septem... [Published American Banking News - Forex - Sep 15 2014]
OXFORD PHARMASCIENCE : Progressing Low Gastric-... [Published 4 Traders - Sep 15 2014]
Oxford Pharmascience updates on Naproxen [Published Stock Market Wire - Sep 15 2014]
Oxford Pharmascience makes strides with naproxe... [Published Proactive Investors.co.uk - Sep 15 2014]
Progression of Reduced Gastric Irritation Naproxen [Published Noodls - Sep 15 2014]
Syrian Arab Republic: Syrian man can smile agai... [Published ReliefWeb - Latest Updates - Jul 18 2014]
DGAP-Adhoc: PAION COMPLETES PRIVATE PLACEMENT W... [Published GlobeNewswire: Advertising News - Jul 17 2014]
Pendopharm gets Health Canada approval for hepa... [Published Pharmaceutical Business Review - Jul 16 2014]
Oxford Pharmascience appoints new non-exec [Published Proactiveinvestors United Kingdom RSS feed - Jul 16 2014]
Health Canada’s Approval of IBAVYR™ Enables Spe... [Published Business Wire Health News - Jul 15 2014]
DGAP-News: PAION GRANTS LICENCE TO REMIMAZOLAM ... [Published GlobeNewswire: Acquisitions News - Jul 09 2014]
UPDATE - Oxford Pharmascience scores line exten... [Published Proactiveinvestors United Kingdom website - Jun 17 2014]
Oxford Pharmascience scores line extension in B... [Published Proactiveinvestors United Kingdom RSS feed - Jun 17 2014]
UPDATE - Oxford Pharmascience pleased with "fan... [Published Proactiveinvestors United Kingdom RSS feed - Jun 02 2014]
UPDATE - Oxford Pharmascience unveils positive ... [Published Proactiveinvestors United Kingdom RSS feed - Jun 02 2014]
Oxford Pharmascience unveils positive NSAID tri... [Published Proactiveinvestors United Kingdom website - Jun 02 2014]
Major Discovery on the Mechanism of Drug Resist... [Published Science Daily - May 28 2014]
Oxehealth receives ?2m of investment [Published TrustNet - May 19 2014]
Oxford Pharmascience appoints clinical partner ... [Published Proactiveinvestors United Kingdom RSS feed - Apr 30 2014]
Innovation Forum [Published TrustNet - Apr 08 2014]
ValiRx, e-Therapeutics, Oxford Pharmascience an... [Published Proactiveinvestors United Kingdom RSS feed - Apr 04 2014]
ValiRx, e-Therapeutics, Oxford Pharmascience an... [Published Proactiveinvestors United Kingdom RSS feed - Apr 04 2014]
ValiRx, e-Therapeutics, Oxford Pharmascience an... [Published Proactiveinvestors United Kingdom RSS feed - Apr 04 2014]
ValiRx, e-Therapeutics, Oxford Pharmascience an... [Published Proactiveinvestors United Kingdom RSS feed - Apr 04 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Syrian Arab Republic: Syrian man can smile agai... [Published ReliefWeb - Latest Updates - Jul 18 2014]
Source: Health Partners International of CanadaCountry: Syrian Arab Republic A Syrian man in his early 20s was injured during the civil war in his country when a bomb hit his neighbourhood. Shrapnel had struck his neck and made him a quadriplegic. “I ...
Health Canada’s Approval of IBAVYR™ Enables Spe... [Published Business Wire Health News - Jul 15 2014]
MONTREAL--(BUSINESS WIRE)--Quebec-based Pendopharm, a division of Pharmascience Inc., today announced Health Canada approval and market availability of IBAVYRTM (ribavirin tablets), the first stand-alone oral ribavirin for the treatment of chronic hepatitis ...
UPDATE - Oxford Pharmascience scores line exten... [Published Proactiveinvestors United Kingdom website - Jun 17 2014]
---ADDS BROKER COMMENT AND SHARE PRICE--- Oxford Pharmascience ( LON:OXP ) has agreed a line extension in Brazil with its partner Aché Pharmaceuticos. The UK company specialises in redeveloping medicines to make them better, safer and easier to take, ...
Oxford Pharmascience unveils positive NSAID tri... [Published Proactiveinvestors United Kingdom website - Jun 02 2014]
Oxford Pharmascience ( LON:OXP ) said the primary and second end points were met in its pilot clinical study of OXP001, its non-steroidal anti-inflammatory drug (NSAID). Oxford, which specialises in reformulating drugs to make them better, safer and ...
Pendopharm Announces Priority Review of New The... [Published Business Wire Health News - Mar 31 2014]
MONTREAL--(BUSINESS WIRE)--New hepatitis C (HCV) treatment regimens have advanced rapidly in recent years, including the recent Health Canada approval of interferon-free therapy. To support patients to access these newest options, Pendopharm, a division ...
1 2

Press Releases

sort by: Date | Relevance
DGAP-Adhoc: PAION COMPLETES PRIVATE PLACEMENT W... [Published GlobeNewswire: Advertising News - Jul 17 2014]
DGAP-News: PAION GRANTS LICENCE TO REMIMAZOLAM ... [Published GlobeNewswire: Acquisitions News - Jul 09 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.